Evaluating the Safety and Efficacy of 177Lu-LNC1011 Injection in a Single-Center, Single-Arm, Open Study in Patients with Prostate-Specific Membrane Antigen (PSMA)-Positive Metastatic Desmoplasia-Resistant Prostate Cancer

Inclusion Criteria: 1. ≥18 years old, male. 2. histologically or cytologically defined prostate cancer, the patients have not been treated or have exhausted all treatment. 3. meet the Prostate Cancer Working Group 3 (PCWG3) diagnosis of metastatic desmoplasia-resistant prostate cancer (mCRPC), including: a) the presence of a desmoplasia level of serum testosterone (serum testosterone \<50 ng/dL or 1.7 nmol/L); b) and the presence of one of the following: - serum PSA progression: PSA \>1 ng/mL and 2 consecutive rises in PSA 1 week apart, 2 greater than 50% of the nadir; or a bone scan suggestive of ≥2 new bone lesions; or CT or MRI suggestive of progression of soft tissue lesions (RECIST 1.1). 4. a physical status score of ≤2 according to Eastern Cooperative Oncology Group (ECOG) criteria. 5. PSMA positivity confirmed by 68Ga -PSMA PET/CT. Exclusion Criteria: Patients who did not meet the requirements as assessed by the investigator.